Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-7479d7b7d-rvbq7 Total loading time: 0 Render date: 2024-07-13T13:10:38.791Z Has data issue: false hasContentIssue false

21 - Clinical Management of Patients with Colorectal Liver Metastasis Using Hepatic Arterial Infusion

from PART III - ORGAN-SPECIFIC CANCERS

Published online by Cambridge University Press:  18 May 2010

By
Fidel David Huitzil Melendez  and
Nancy Kemeny
Edited by
Jean-François H. Geschwind  and
Michael C. Soulen
Fidel David Huitzil Melendez
Affiliation:
Gastrointestinal Oncology Fellow Memorial Sloan-Kettering Cancer Center, New York, NY
Nancy Kemeny
Affiliation:
Attending Physician Memorial Sloan-Kettering Cancer Center Professor of Medicine, Weill Medical College of Cornell University New York, NY
Jean-François H. Geschwind
Affiliation:
The Johns Hopkins University School of Medicine
Michael C. Soulen
Affiliation:
University of Pennsylvania School of Medicine
Get access

Summary

Liver metastases from colorectal cancer is a suitable clinical model for regional drug delivery for several reasons: as a result of portal venous drainage, the liver can be the first and only site of metastatic disease in patients with colorectal cancer (1). This is in contrast with other gastrointestinal malignancies, in which liver metastases are frequently a marker of widespread disease, as is the case of gastric cancer and pancreatic cancer (2). In addition, colon cancer has favorable tumor biology compared with other gastrointestinal or non-gastrointestinal malignancies. When liver resections were performed under the same criteria for liver metastases from colon cancer and from gastric cancer, 5-year overall survival was 30% for colon cancer patients and 0% for gastric cancer patients (3). Furthermore, the hepatic artery (HA) is the main blood supply of liver metastases (4). Totally implantable infusion systems have been developed (5), and the surgical techniques have improved (5), allowing a higher percentage of patients to receive regional treatment for longer periods of time.

Identification of ideal candidates is critical for optimal clinical results. Selection criteria focus on identifying patients with liver-only metastatic disease, with suitable hepatic arterial anatomy for pump placement. For this purpose, work-up should include computed tomography scan of the chest, abdomen and pelvis with liver angiography. Positron emission tomographic scans are not routinely performed, but they can be helpful in determining the nature of enlarged periportal lymph nodes or other indeterminate lesions (6).

Type
Chapter
Information
Interventional Oncology
Principles and Practice
 , pp. 249 - 263
Publisher: Cambridge University Press
Print publication year: 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Weiss, L, Grundmann, E, Torhorst, J, et al. Haematogenous metastatic patterns in colonic carcinoma: An analysis of 1541 necropsies. J Pathol, 1986 Nov; 150(3): 195–203.CrossRefGoogle ScholarPubMed
Kemeny N, Kemeny M, and Lawrence TS. Liver Metastases. In: Abeloff, A J, Niederhuber, J E, and Kastan, M B et al. (eds) Clinical Oncology, pp. 1141–1178.Philadelphia: Elsevier, 2004.Google Scholar
Imamura, H, Matsuyama, Y, Shimada, R, et al. A study of factors influencing prognosis after resection of hepatic metastases from colorectal and gastric carcinoma. Am J Gastroenterol, 2001 Nov; 96(11): 3178–3184.CrossRefGoogle ScholarPubMed
Sigurdson, E R, Ridge, J A, Kemeny, N, et al. Tumor and liver drug uptake following hepatic artery and portal vein infusion. J Clin Oncol, 1987; 5(11): 1836–1840.CrossRefGoogle ScholarPubMed
Allen, P J, Nissan, A, Picon, A I, et al. Technical complications and durability of hepatic artery infusion pumps for unresectable colorectal liver metastases: An institutional experience of 544 consecutive cases. J Am Coll Surg, 2005; 201(1): 57–65.CrossRefGoogle ScholarPubMed
Ruers, T J, Langenhoff, B S, Neeleman, N, et al. Value of positron emission tomography with [F-18]fluoro-deoxyglucose in patients with colorectal liver metastases: A prospective study. J Clin Oncol, 2002; 20(2): 388–395.CrossRefGoogle Scholar
Adam, R, Laurent, A, Azoulay, D, et al. Two-stage hepatectomy: A planned strategy to treat irresectable liver tumors. Ann Surg, 2000; 232(6): 777–785.CrossRefGoogle ScholarPubMed
Nordlinger, B, Vaillant, J C, Guiguet, M, et al. Survival benefit of repeat liver resections for recurrent colorectal metastases: 143 cases. Association Francaise de Chirurgie. J Clin Oncol, 1994; 12(7): 1491–1496.CrossRefGoogle ScholarPubMed
Fong, Y, Fortner, J, Sun, R L, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: Analysis of 1001 consecutive cases. Ann Surg, 1999; 230(3): 309–318; discussion 318–321.CrossRefGoogle ScholarPubMed
Lorenz, M and Muller, H H. Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma. J Clin Oncol, 2000; 18(2): 243–254.CrossRefGoogle ScholarPubMed
Kemeny, N E, Niedzwiecki, D, Hollis, D R, et al. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: A randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol, 2006; 24(9): 1395–1403.CrossRefGoogle Scholar
Kemeny, N, Daly, J, Reichman, B, et al. Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma: A randomized trial. Ann Intern Med, 1987; 107(4): 459–465.CrossRefGoogle ScholarPubMed
Chang, A E, Schneider, P D, Sugarbaker, P H, et al. A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg, 1987; 206(6): 685–693.CrossRefGoogle ScholarPubMed
Hohn, D C, Stagg, R J, Friedman, M A, et al. A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: The Northern California Oncology Group trial. J Clin Oncol, 1989; 7(11): 1646–1654.CrossRefGoogle ScholarPubMed
Wagman, L D, Kemeny, M M, Leong, L, et al. A prospective, randomized evaluation of the treatment of colorectal cancer metastatic to the liver. J Clin Oncol, 1990; 8(11): 1885–1893.CrossRefGoogle ScholarPubMed
Martin, J K Jr, Connell, M J, Wieand, H S, et al. Intra-arterial floxuridine vs. systemic fluorouracil for hepatic metastases from colorectal cancer: A randomized trial. Arch Surg, 1990; 125(8): 1022–1027.CrossRefGoogle ScholarPubMed
Rougier, P, Laplanche, A, Huguier, M, et al. Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: Long-term results of a prospective randomized trial. J Clin Oncol, 1992; 10(7): 1112–1118.CrossRefGoogle ScholarPubMed
Allen-Mersh, T G, Earlam, S, Fordy, C, et al. Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases. Lancet, 1994; 344(8932): 1255–1260.CrossRefGoogle ScholarPubMed
Kerr, D J, McArdle, C S, Ledermann, J, et al. Medical Research Council's Colorectal Cancer Study Group; European Organisation for Research and Treatment of Cancer Colorectal Cancer Study Group. Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: A multicentre randomised trial. Lancet, 2003; 361(9355): 368–373.CrossRefGoogle Scholar
Kemeny, N, Steiter, K, Niedzweiecki, D, et al. A randomized trial of intrahepatic infusion of fluorouridine (FUDR) with dexamethasone versus FUDR alone in the treatment of metastatic colorectal cancer. Cancer, 1992; 69: 327–334.3.0.CO;2-U>CrossRefGoogle Scholar
Civalleri, D, DeCian, F, Pellicci, R, et al. Differential device performances for hepatic arterial chemotherapy: A technical report on totally implantable pumps and ports for both continuous and bolus infusion. Eur Surg Res, 1998; 30(1): 26–33.CrossRefGoogle ScholarPubMed
Strasberg, S M, Dehdashti, F, Siegel, B A, et al. Survival of patients evaluated by FDG-PET before hepatic resection for metastatic colorectal carcinoma: A prospective database study. Ann Surg, 2001; 233(3): 293–299.CrossRefGoogle ScholarPubMed
Rougier, P, Laplanche, A, Huguier, M, et al. Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: Long-term results of a prospective randomized trial. J Clin Oncol, 1992; 10(7): 1112–1118.CrossRefGoogle ScholarPubMed
Kemeny, N, Seiter, K, Niedzwiecki, D, et al. A randomized trial of intrahepatic infusion of fluorodeoxyuridine with dexamethasone versus fluorodeoxyuridine alone in the treatment of metastatic colorectal cancer. Cancer, 1992; 69(2): 327–334.3.0.CO;2-U>CrossRefGoogle ScholarPubMed
Kemeny, N, Gonen, M, Sullivan, D, et al. Phase I study of hepatic arterial infusion of floxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer. J Clin Oncol, 2001; 19(10): 2687–2695.CrossRefGoogle ScholarPubMed
Kemeny, N, Jarnagin, W, Paty, P, et al. Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. J Clin Oncol, 2005; 23(22): 4888–4896.CrossRefGoogle ScholarPubMed
Allen, P J, Kemeny, N, Jarnagin, W, et al. Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases. J Gastrointest Surg, 2003; 7(1): 109–115; discussion 116–117.CrossRefGoogle ScholarPubMed
Wein, A, Riedel, C, Brückl, W, et al. Neoadjuvant treatment with weekly high-dose 5-fluorouracil as 24-hour infusion, folinic acid and oxaliplatin in patients with primary resectable liver metastases of colorectal cancer. Oncology, 2003; 64(2): 131–138.CrossRefGoogle ScholarPubMed
Alberts, S R, Horvath, W L, Sternfeld, W C, et al. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: A North Central Cancer Treatment Group phase II study. J Clin Oncol, 2005; 23(36): 9243–9249.CrossRefGoogle ScholarPubMed
Tournigand, C, André, T, Achille, E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol, 2004; 22(2): 229–237.CrossRefGoogle ScholarPubMed
Hurwitz, H, Fehrenbacher, L, Novotny, W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med, 2004; 350(23): 2335–2342.CrossRefGoogle ScholarPubMed
Masi, G, Cupini, S, Marcucci, L, et al. Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer. Ann Surg Oncol, 2006; 13(1): 58–65.CrossRefGoogle ScholarPubMed
Gaspar, E M, Artigas, V, Montserrat, E. Single-centre study of L-OHP/5-FU/LV before liver surgery in patients with NOT optimally resectable colorectal cancer isolated liver metastases. ASCO Annual Meeting, 2003, American Society of Clinical Oncology, Chicago, Illinois.Google Scholar
Clavien, P A, Selzner, N, Morse, M, et al. Downstaging of hepatocellular carcinoma and liver metastases from colorectal cancer by selective intra-arterial chemotherapy. Surgery, 2002; 131(4): 433–442.CrossRefGoogle ScholarPubMed
Kemeny, N, Jarnagin, W, Paty, P, et al. Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. J Clin Oncol, 2005; 23(22): 4888–4896.CrossRefGoogle Scholar
Noda, M, Yanagi, H, Yoshikawa, R. Second-look hepatectomy after pharmacokinetic modulating chemotherapy (PMC) combination with hepatic arterial 5FU infusion and oral UFT in patients with unresectable hepatic colorectal metastases. ASCO Annual Meeting, 2004, American Society of Clinical Oncology, New Orleans, Louisiana.Google Scholar
Garassino, I C, Rimassa, L, Zuradelli, M. Definitive results of hybrid chemotherapy with intravenous (iv) oxaliplatin (OXA) and folinic acid (FA), and intra-hepatic infusion (HAI) of 5-fluorouracil (5-FU) in patients with colorectal liver metastases. ASCO Annual Meeting, 2005, American Society of Clinical Oncology, Atlanta, Georgia.Google Scholar
Zelek, L, Bugat, R, Cherqui, D, et al. Multimodal therapy with intravenous biweekly leucovorin, 5-fluorouracil and irinotecan combined with hepatic arterial infusion pirarubicin in non-resectable hepatic metastases from colorectal cancer (a European Association for Research in Oncology trial). Ann Oncol, 2003; 14(10): 1537–1542.CrossRefGoogle Scholar
Bouchahda, M, Adam R, Giacchetti S, et al. Effective salvage therapy of liver-only colorectal cancer metastases with chronomodulated irinotecan-fluorouracil-oxaliplatin via hepatic artery infusion. ASCO Annual Meeting, 2006, American Society of Clinical Oncology, Atlanta, Georgia.Google Scholar
Adam, R, Delvart, V, Pascal, G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: A model to predict long-term survival. Ann Surg, 2004; 240(4): 644–657; discussion 657–658.Google ScholarPubMed
Topal, B, Kaufman, L, Aerts, R. Patterns of failure following curative resection of colorectal liver metastases. Eur J Surg Oncol, 2003 Apr;29(3):248–53.CrossRefGoogle ScholarPubMed
White, R R, Avital, I, Sofocleous, C T, et al. Rates and patterns of recurrence for percutaneous radiofrequency ablation and open wedge resection for solitary colorectal liver metastasis. J Gastrointestinal Surg, 2007; 11(3): 256–263.CrossRefGoogle ScholarPubMed
Kornprat, P, Jarnagin, W R, Gonen, M, et al. Outcome after hepatectomy for multiple (four or more) colorectal metastases in the era of effective chemotherapy. Ann Surg Oncol, 2007; 14(3): 1151–1160.CrossRefGoogle ScholarPubMed
Portier, G, Elias, D, Bouche, O, et al. Adjuvant systemic chemotherapy using 5-fluorouracil and folinic acid after resection of liver metastases from colorectal origin. Proc Am Soc Clin Oncol, 21: 2002; (abstr 528).Google Scholar
Sargent, D J, Wieand, H S, Haller, D G, et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol, 2005; 23(34): 8664–8670.CrossRefGoogle ScholarPubMed
Langer, B, Bleiberg H, Labianca R, et al. Fluorouracil (FU) plus l-leucovorin (l-LV) versus observation after potentially curative resection of liver or lung metastases from colorectal cancer (CRC): Results of the ENG (EORTC/NCIC CTG/GIVIO) randomized trial. ASCO Annual Meeting, 2002, American Society of Clinical Oncology, Orlando, Florida.Google Scholar
Lorenz, M, Müller, H H, Schramm, H, et al. Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. German Cooperative on Liver Metastases (Arbeitsgruppe Lebermetastasen). Ann Surg, 1998; 228(6): 756–762.CrossRefGoogle Scholar
Kemeny, N, Huang, Y, Cohen, A M, et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med, 1999; 341(27): 2039–2048.CrossRefGoogle ScholarPubMed
Kemeny, N E and Gonen, M. Hepatic arterial infusion after liver resection. N Engl J Med, 2005; 352(7): 734–735.CrossRefGoogle ScholarPubMed
Tono, T, Hasuike, Y, Ohzato, H, et al. Limited but definite efficacy of prophylactic hepatic arterial infusion chemotherapy after curative resection of colorectal liver metastases: A randomized study. Cancer, 2000; 88(7): 1549–1556.3.0.CO;2-K>CrossRefGoogle ScholarPubMed
Kemeny, M M, Adak, S, Gray, B, et al. Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: Surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy – an intergroup study. J Clin Oncol, 2002; 20(6): 1499–1505.Google ScholarPubMed
Lygidakis, N J, Sgourakis, G, Vlachos, L, et al. Metastatic liver disease of colorectal origin: The value of locoregional immunochemotherapy combined with systemic chemotherapy following liver resection. Results of a prospective randomized study. Hepatogastroenterology, 2001; 48(42): 1685–1691.Google ScholarPubMed
Kusunoki, M, Yanagi, H, Noda, M, et al. Results of pharmacokinetic modulating chemotherapy in combination with hepatic arterial 5-fluorouracil infusion and oral UFT after resection of hepatic colorectal metastases. Cancer, 2000; 89(6): 1228–1235.3.0.CO;2-O>CrossRefGoogle ScholarPubMed
Kemeny, N E, Niedzwiecki D, Hollis DR, et al. Hepatic arterial infusion (HAI) versus systemic therapy for hepatic metastases from colorectal cancer; a CALGB randomized trial of efficacy, quality of life (QOL), cost effectiveness, and molecular markers. ASCO Annual Meeting, 2003, American Society of Clinical Oncology, Chicago, Illinois.Google Scholar
Kemeny, N, Cohen, A, Seiter, K, et al. Randomized trial of hepatic arterial floxuridine, mitomycin, and carmustine versus floxuridine alone in previously treated patients with liver metastases from colorectal cancer. J Clin Oncol, 1993; 11(2): 330–335.CrossRefGoogle ScholarPubMed
Kemeny, N, Conti, J A, Cohen, A, et al. Phase II study of hepatic arterial floxuridine, leucovorin, and dexamethasone for unresectable liver metastases from colorectal carcinoma. J Clin Oncol, 1994; 12(11): 2288–2295.CrossRefGoogle ScholarPubMed
Kemeny, N, Eid, A, Stockman, J, et al. Hepatic arterial infusion of floxuridine and dexamethasone plus high-dose mitomycin C for patients with unresectable hepatic metastases from colorectal carcinoma. J Surg Oncol, 2005; 91(2): 97–101.CrossRefGoogle ScholarPubMed
Rothenberg, M L, Cox, J V, DeVore, R F, et al. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer, 1999; 85(4): 786–795.3.0.CO;2-9>CrossRefGoogle ScholarPubMed
Rothenberg, M L, Oza, A M, Bigelow, R H, et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol, 2003; 21(11): 2059–2069.CrossRefGoogle ScholarPubMed
Giantonio, B J, Catalano PJ, Meropol NJ, et al. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200. ASCO Annual Meeting, 2005, American Society of Clinical Oncology, Orlando, Florida.Google Scholar
Saltz, L B, Lenz H, Hochster H, et al. Randomized Phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. ASCO Annual Meeting, 2005, American Society of Clinical Oncology, Orlando, Florida.Google Scholar
Pozzo, C, Basso M, Quirino M, et al. Long-term follow-up of colorectal cancer (CRC) patients treated with neoadjuvant chemotherapy with irinotecan and fluorouracil plus folinic acid (5-FU/FA) for unresectable liver metastases. ASCO Annual Meeting, 2006, American Society of Clinical Oncology, Atlanta, Georgia.Google Scholar
Alberts, S R, Horvath, W L, Sternfeld, W C, et al. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: A North Central Cancer Treatment Group phase II study. J Clin Oncol, 2005; 23(36): 9243–9249.CrossRefGoogle ScholarPubMed
Quenet, F, Nordlinger B, Rivoire M, et al. Resection of previously unresectable liver metastases from colorectal cancer (LMCRC) after chemotherapy (CT) with CPT-11/L-OHP/LV5FU (FOLFIRINOX): A prospective phase II trial. ASCO Annual Meeting, 2004, American Society of Clinical Oncology, New Orleans, Louisiana.Google Scholar
Abad, A, Anton A, Massuti B, et al. Resectability of liver metastases (LM) in patients with advanced colorectal cancer (ACRC) after treatment with the combination of oxaliplatin (OXA), irinotecan (IRI) and 5FU: Final results of a phase II study. ASCO Annual Meeting, 2005, American Society of Clinical Oncology, Orlando, Florida.Google Scholar
Ho, W M, Ma, B, Mok, T, et al. Liver resection after irinotecan, 5-fluorouracil, and folinic acid for patients with unresectable colorectal liver metastases: A multicenter phase II study by the Cancer Therapeutic Research Group. Med Oncol, 2005; 22(3): 303–312.CrossRefGoogle ScholarPubMed
Wein, A, Riedel, C, Köckerling, F, et al. Impact of surgery on survival in palliative patients with metastatic colorectal cancer after first line treatment with weekly 24-hour infusion of high-dose 5-fluorouracil and folinic acid. Ann Oncol, 2001; 12(12): 1721–1727.CrossRefGoogle ScholarPubMed
Clavien, P A, Selzner, N, Morse, M, et al. Downstaging of hepatocellular carcinoma and liver metastases from colorectal cancer by selective intra-arterial chemotherapy. Surgery, 2002; 131(4): 433–442.CrossRefGoogle ScholarPubMed
Huitzil, F D, Capanu, M, Paty, P. Predictive factors for resection of unresectable metastases from colorectal cancer in patients treated with hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone (DEX) plus IV oxaliplatin (Oxali) and irinotecan (CPT). 2008 Gastrointestinal Cancers Symposium 2008. Orlando, Florida.Google Scholar
Zelek, L, Bugat, R, Cherqui, D, et al. Multimodal therapy with intravenous biweekly leucovorin, 5-fluorouracil and irinotecan combined with hepatic arterial infusion pirarubicin in non-resectable hepatic metastases from colorectal cancer (a European Association for Research in Oncology trial). Ann Oncol, 2003; 14(10): 1537–1542.CrossRefGoogle Scholar
Lorenz, M, Müller, H H, Schramm, H, et al. Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. German Cooperative on Liver Metastases (Arbeitsgruppe Lebermetastasen). Ann Surg, 1998; 228(6): 756–762.CrossRefGoogle Scholar
Tono, T, Hasuike, Y, Ohzato, H, et al. Limited but definite efficacy of prophylactic hepatic arterial infusion chemotherapy after curative resection of colorectal liver metastases: A randomized study. Cancer, 2000; 88(7): 1549–1556.3.0.CO;2-K>CrossRefGoogle ScholarPubMed
Kemeny, M M, Adak, S, Gray, B, Macdonald, J S, et al. Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: Surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy – an intergroup study. J Clin Oncol, 2002; 20(6): 1499–1505.Google ScholarPubMed
Lygidakis, N J, Sgourakis, G, Vlachos, L, et al. Metastatic liver disease of colorectal origin: The value of locoregional immunochemotherapy combined with systemic chemotherapy following liver resection. Results of a prospective randomized study. Hepatogastroenterology, 2001; 48(42): 1685–1691.Google ScholarPubMed
Asahara, T, Kikkawa, M, Okajima, M, et al. Studies of postoperative transarterial infusion chemotherapy for liver metastasis of colorectal carcinoma after hepatectomy. Hepatogastroenterology, 1998; 45(21): 805–811.Google ScholarPubMed
Kusunoki, M, Yanagi H, , Noda, M, et al. Results of pharmacokinetic modulating chemotherapy in combination with hepatic arterial 5-fluorouracil infusion and oral UFT after resection of hepatic colorectal metastases. Cancer, 2000; 89(6): 1228–1235.3.0.CO;2-O>CrossRefGoogle ScholarPubMed
Carnaghi, C, Santoro, A, Rimassa, L, et al. The efficacy of hybrid chemotherapy with intravenous oxaliplatin and folinic acid and intra-hepatic infusion of 5-fluorouracil in patients with colorectal liver metastases: A phase II study. Invest New Drugs, 2007; 25(5): 479–485.CrossRefGoogle ScholarPubMed
Cunningham, D, Humblet, Y, Siena, S. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. NEJM, 2004; 351(4): 337–345.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×